Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity.

Ten of 14 schizophrenic patients completed a 6-week pilot study with a new substituted benzamide, remoxipride. The final median dose was 600 mg/day (range 300-1200) corresponding to a plasma concentration of 5.16 mumol/l (1.55-11.50). Remoxipride reduced the psychotic symptomatology, especially hallucinations and delusions. The total Brief Psychiatric Rating Scale score decreased from 33.5 to 13.0 (P less than 0.01). Few side effects occurred; four patients had weak extrapyramidal symptoms, and four were slightly sedated. No cardiovascular side effects occurred. Prolactin increased, but apparently less than during sulpiride treatment.